Medications for Hormone Receptor Positive Her2 Negative Breast Cancer

5 results

  • ibrance - palbociclib capsule

    (Palbociclib)
    Pfizer Laboratories Div Pfizer Inc
    IBRANCE treats HR-positive, HER2-negative advanced or metastatic breast cancer in adults, combined with an aromatase inhibitor or fulvestrant. It also treats PIK3CA-mutated, endocrine-resistant cases with inavolisib and fulvestrant, and HR-positive, HER2-positive metastatic breast cancer with trastuzumab and endocrine therapy for maintenance.
    Medication Details
    Savings Programs
    1
    Drug Interactions

  • ibrance - palbociclib tablet, film coated

    (Palbociclib)
    Pfizer Laboratories Div Pfizer Inc
    IBRANCE treats adults with HR-positive, HER2-negative advanced or metastatic breast cancer alongside an aromatase inhibitor or fulvestrant. It also treats endocrine-resistant, PIK3CA-mutated HER2-negative metastatic breast cancer, and HR-positive, HER2-positive metastatic breast cancer as maintenance therapy with trastuzumab and endocrine therapy.
    Medication Details
    Drug Interactions

  • piqray - alpelisib tablet

    (Alpelisib)
    Novartis Pharmaceuticals Corporation
    PIQRAY is used with fulvestrant to treat adults with HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, after progression on an endocrine-based regimen, as detected by an FDA-approved test.
    Medication Details
    Drug Interactions

  • trodelvy - sacituzumab govitecan powder, for solution

    (Sacituzumab Govitecan)
    Gilead Sciences, Inc.
    Trodelvy treats unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in adults - as first-line therapy (alone or with pembrolizumab for PD-L1-positive tumors) or second-line or later - and HR-positive, HER2-negative breast cancer after endocrine and two or more systemic therapies.
    Medication Details
    Drug Interactions

  • truqap - capivasertib tablet, film coated

    (Capivasertib)
    Astrazeneca Pharmaceuticals Lp
    Truqap is a kinase inhibitor used with fulvestrant to treat adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN alterations, and with abiraterone and prednisone to treat adults with PTEN-deficient metastatic prostate cancer.
    Medication Details
    Drug Interactions